NASDAQ: VBIV - VBI Vaccines Inc.

Доходность за полгода: -95.92%
Дивидендная доходность: 0.00%
Сектор: Healthcare

График акции VBI Vaccines Inc.


О компании VBI Vaccines Inc.

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.

подробнее
In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

IPO date 1995-08-18
ISIN CA91822J1030
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 0.25
Сайт https://www.vbivaccines.com
Цена ао 0.58
Изменение цены за день: 0% (0.0282)
Изменение цены за неделю: 0% (0.0282)
Изменение цены за месяц: 0% (0.0282)
Изменение цены за 3 месяца: 0% (0.0282)
Изменение цены за полгода: -95.92% (0.692)
Изменение цены за год: -95.22% (0.59)
Изменение цены за 3 года: -98.87% (2.49)
Изменение цены за 5 лет: -95.6% (0.6405)
Изменение цены за 10 лет: 0% (0.0282)
Изменение цены с начала года: 0% (0.0282)

Недооценка

Название Значение Оценка
P/S 0.9865 9
P/BV 1.14 9
P/E 0 0
EV/EBITDA -0.7112 0
Итого: 6

Эффективность

Название Значение Оценка
ROA, % -106.77 0
ROE, % -1233.37 0
Итого: 0

Дивиденды

Название Значение Оценка
Div yield, % 0 0
DSI 0.7 7
Итого: 1.16

Долг

Название Значение Оценка
Debt/EBITDA -0.9947 10
Итого: 8.2

Импульс роста

Название Значение Оценка
Доходность Revenue, % 294.64 10
Доходность Ebitda, % 15.66 3
Доходность EPS, % -60.52 0
Итого: 4.6

Институционалы Объем Доля, %
Perceptive Advisors LLC 1381355 5.83
Alyeska Investment Group, L.P. 696736 2.94
Geode Capital Management, LLC 138729 0.59
Blackrock Inc. 111960 0.47
Cambridge Investment Research Advisors Inc. 93556 0.39
Millennium Management LLC 71422 0.3
Vanguard Group Inc 64522 0.27
General American Investors Company Inc 62583 0.26
Morgan Stanley 34973 0.15
Northern Trust Corporation 32992 0.14



Руководитель Должность Оплата Год рождения
Mr. Jeffery R. Baxter FCMA President, CEO & Director 908.06k 1961 (64 года)
Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D. Chief Medical Officer 544.52k 1955 (70 лет)
Ms. Nell Beattie CFO, Head of Corporate Development & Director N/A 1988 (37 лет)
Ms. Athena Kartsaklis Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer N/A 1965 (60 лет)
Mr. Avi Mazaltov Global Head of Manufacturing & GM of SciVac N/A 1962 (63 года)
Mr. Misha Nossov Senior VP of Global Commercial Supply Strategy & Head of Europe N/A
Mr. John Robert Dillman Chief Commercial Officer N/A 1968 (57 лет)
Dr. David Evander Anderson Ph.D. Chief Scientific Officer 1970 (55 лет)
Ms. Nicole Anderson Director of Corporate Communications & Investor Relations
Mr. T. Adam Buckley B.Sc., MBA Senior Vice President of Business Development 1976 (49 лет)

Адрес: United States, Cambridge. MA, 160 Second Street - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.vbivaccines.com